Advertisement

Topics

Companies Related to "Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC" [Most Relevant Company Matches] RSS

21:42 EDT 19th August 2018 | BioPortfolio

Here are the most relevant search results for "Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC" found in our extensive corporate database of over 50,000 company records.

Showing "Granulocyte Macrophage Colony Stimulating Factor Zidovudine Phase Study" Companies 1–25 of 1,600+

Extremely Relevant

Generon (Shanghai) Corporation Ltd.

Generon (Shanghai) Corporation Ltd. is a biotechnology company based in China with a mission to develop innovative biological therapies for patients in China and around the world. F-627 is a newer generation recombinant human granulocyte colony-stimulating factor (G-CSF) that helps the cancer patients to recover from chemotherapy induced neutropenia, a pot...


Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...

Dragon Pharmaceutical Inc

Dragon Pharmaceutical Inc. (Ticker: OTCBB:DRUG, TSX: DDD, BBSE: DRP) is an international pharmaceutical company headquartered in Vancouver, Canada, with 4 production facilities located in Datong and Nanjing, China. The Company currently produces more than 40 products in China and markets them in China as well as internationally. These products are organized under 3 distinct business divisions: a P...


Relevant

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

aCOLyte

The aCOLyte colony counter is available with two levels of functionality, Click’n’Count and SuperCount. Click'n'Count allows you to simply point to each colony and click to count. Click'n'Count is as fast as any lightbox colony counter and will fit seamlessly into any laboratory. There is no longer a need for time-consuming data transcription. Images plateIDs and counts are all saved automat...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

BIOCON, INC.

Since 1978 BIOCON has provided highly reliable, custom small animal research services to the region’s leading biomedical scientists. Whether your study involves small animal housing, breeding and colony management, research study applications, safety testing, custom antibody production or fully-compliant Good Laboratory Practices, BIOCON implements our client’s research initiative with dedicat...

Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

ProFibrix B.V.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant in development to stop bleeding after or during surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, is stable at room temperature, and has shown to be safe and efficacious...

Iconic Therapeutics, Inc.

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Fit Factor Network, Inc.

Fit Factor Network, Inc. was founded by Hillsborough County physical education teacher, Scott Owen, for the purpose of improving the health of children and families. The company produces the Fit Factor Kids DVD - a 45 minute exercise DVD developed for and hosted by kids. The DVD is comprised of six workouts and three educational Fit Tip segments. For additional information, visit www.FitFactorKids...

ProtoCOL HR

ProtoCOL HR is a high resolution automatic colony counting and zone sizing system, able to count extremely small colonies and measure zones with a very high degree of accuracy. This colony counter and zone sizer system offers incredibly accurate and repeatable results with superior performance for the most challenging of sample types and applications.

Accredo Nova Factor

For more than 20 years, Accredo Nova Factor has provided nationwide distribution and pharmaceutical care management for the biopharmaceutical industry. Accredo Nova Factor currently has 15 product lines that are dispensed from its specialty pharmacy headquarters in Memphis, Tenn. The products are usually shipped overnight to the patients' homes, where patients are trained to reconstitute and self-...

Proneuron Biotechnologies (Israel) Limited

Proneuron Biotechnologies is developing therapies for neurological, ophthalmologic and immune-related disorders such as spinal cord injuries, multiple sclerosis, glaucoma, Parkinson's disease and Alzheimer's diseases. The technology derives from research on key mechanisms in the dialogue between the nervous and immune systems originating from The Weizmann Institute of Science. Proneuron's novel st...

Synbiosis

Synbiosis is a world leading supplier of automatic colony counting and zone measurement systems in microbiology and pharmaceutical applications. The hallmark of all Synbiosis systems is that they will improve the efficiency, reliability and productivity of any laboratory through the use of automated techniques. Synbiosis products are used in the pharmaceutical, healthcare and food manufacturing in...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


More From BioPortfolio on "Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks